Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 213

1.

Clearance of hepatitis C virus is associated with early and potent but narrowly-directed, Envelope-specific antibodies.

Walker MR, Leung P, Eltahla AA, Underwood A, Abayasingam A, Brasher NA, Li H, Wu BR, Maher L, Luciani F, Lloyd AR, Bull RA.

Sci Rep. 2019 Sep 16;9(1):13300. doi: 10.1038/s41598-019-49454-w.

2.

Contribution of individual psychological and psychosocial factors to symptom severity and time-to-recovery after naturally-occurring acute infective illness: The Dubbo Infection Outcomes Study (DIOS).

Cvejic E, Li H, Hickie IB, Wakefield D, Lloyd AR, Vollmer-Conna U.

Brain Behav Immun. 2019 Nov;82:76-83. doi: 10.1016/j.bbi.2019.07.034. Epub 2019 Jul 31.

PMID:
31376496
3.

Single-Dose Vaccination with a Hepatotropic Adeno-associated Virus Efficiently Localizes T Cell Immunity in the Liver with the Potential To Confer Rapid Protection against Hepatitis C Virus.

Mekonnen ZA, Grubor-Bauk B, English K, Leung P, Masavuli MG, Shrestha AC, Bertolino P, Bowen DG, Lloyd AR, Gowans EJ, Wijesundara DK.

J Virol. 2019 Sep 12;93(19). pii: e00202-19. doi: 10.1128/JVI.00202-19. Print 2019 Oct 1.

PMID:
31292249
4.

Severe Eosinophilic Meningoencephalitis Secondary to Suspected Neuroangiostrongyliasis with a Good Clinical Outcome.

Chiong F, Lloyd AR, Post JJ.

Case Rep Infect Dis. 2019 May 26;2019:4037196. doi: 10.1155/2019/4037196. eCollection 2019.

5.

A method for detecting hepatitis C envelope specific memory B cells from multiple genotypes using cocktail E2 tetramers.

Wu BR, Eltahla AA, Keoshkerian E, Walker MR, Underwood A, Brasher NA, Agapiou D, Lloyd AR, Bull RA.

J Immunol Methods. 2019 Sep;472:65-74. doi: 10.1016/j.jim.2019.06.016. Epub 2019 Jun 19.

PMID:
31226262
6.

Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.

Keck ZY, Pierce BG, Lau P, Lu J, Wang Y, Underwood A, Bull RA, Prentoe J, Velázquez-Moctezuma R, Walker MR, Luciani F, Guest JD, Fauvelle C, Baumert TF, Bukh J, Lloyd AR, Foung SKH.

PLoS Pathog. 2019 May 17;15(5):e1007772. doi: 10.1371/journal.ppat.1007772. eCollection 2019 May.

7.

Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for Protection.

Mekonnen ZA, Grubor-Bauk B, Masavuli MG, Shrestha AC, Ranasinghe C, Bull RA, Lloyd AR, Gowans EJ, Wijesundara DK.

Front Cell Infect Microbiol. 2019 Apr 3;9:91. doi: 10.3389/fcimb.2019.00091. eCollection 2019. Review.

8.

Scale-up of hepatitis C treatment in prisons is key to national elimination.

Papaluca T, Hellard ME, Thompson AJV, Lloyd AR.

Med J Aust. 2019 May;210(9):391-393.e1. doi: 10.5694/mja2.50140. Epub 2019 Apr 9. No abstract available.

PMID:
30968417
9.

Response to Commentary: 'Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, and Chronic Fatigue: Three Distinct Entities Requiring Complete Different Approaches'.

Beilharz JE, Fatt SJ, Cvejic E, Lloyd AR, Vollmer-Conna U.

Curr Rheumatol Rep. 2019 Apr 6;21(6):22. doi: 10.1007/s11926-019-0824-y. Review. No abstract available.

PMID:
30955109
10.

Sex discrepancies in the protective effect of opioid agonist therapy on incident hepatitis C infection.

Geddes L, Iversen J, Wand H, Esmaeili A, Tsui J, Hellard M, Dore G, Grebely J, Dietze P, Bruneau J, Prins M, Morris MD, Shoukry NH, Lloyd AR, Kim AY, Lauer G, Cox AL, Page K, Maher L; InC3 Collaborative.

Clin Infect Dis. 2019 Feb 28. pii: ciz162. doi: 10.1093/cid/ciz162. [Epub ahead of print]

PMID:
30816419
11.

A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015.

Bartlett SR, Applegate TL, Jacka BP, Martinello M, Lamoury FM, Danta M, Bradshaw D, Shaw D, Lloyd AR, Hellard M, Dore GJ, Matthews GV, Grebely J.

J Int AIDS Soc. 2019 Feb;22(2):e25222. doi: 10.1002/jia2.25222.

12.

The Invisible Burden of Chronic Fatigue in the Community: a Narrative Review.

Fatt SJ, Cvejic E, Lloyd AR, Vollmer-Conna U, Beilharz JE.

Curr Rheumatol Rep. 2019 Feb 11;21(2):5. doi: 10.1007/s11926-019-0804-2. Review.

PMID:
30741357
13.

Genomic variability of within-host hepatitis C variants in acute infection.

Rodrigo C, Leung P, Lloyd AR, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Cox AL, Osburn W, Kim AY, Shoukry NH, Lauer GM, Maher L, Schinkel J, Prins M, Hellard M, Eltahla AA; InC3 Collaborative.

J Viral Hepat. 2019 Apr;26(4):476-484. doi: 10.1111/jvh.13051. Epub 2019 Jan 22.

PMID:
30578702
14.

Chemokine-Regulated Recruitment of Antigen-Specific T-Cell Subpopulations to the Liver in Acute and Chronic Hepatitis C Infection.

Pirozyan MR, Nguyen N, Cameron B, Luciani F, Bull RA, Zekry A, Lloyd AR.

J Infect Dis. 2019 Apr 16;219(9):1430-1438. doi: 10.1093/infdis/jiy679.

PMID:
30496498
15.

Understanding the Determinants of BnAb Induction in Acute HCV Infection.

Underwood AP, Walker MR, Brasher NA, Eltahla AA, Maher L, Luciani F, Lloyd AR, Bull RA.

Viruses. 2018 Nov 21;10(11). pii: E659. doi: 10.3390/v10110659.

16.

Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison.

Lafferty L, Rance J, Grebely J, Lloyd AR, Dore GJ, Treloar C; SToP-C Study Group.

J Viral Hepat. 2018 Dec;25(12):1526-1532. doi: 10.1111/jvh.12987. Epub 2018 Sep 19.

PMID:
30141261
17.

Personalised relaxation practice to improve sleep and functioning in patients with chronic fatigue syndrome and depression: study protocol for a randomised controlled trial.

Macnamara CL, Cvejic E, Parker GB, Lloyd AR, Lee G, Beilharz JE, Vollmer-Conna U.

Trials. 2018 Jul 11;19(1):371. doi: 10.1186/s13063-018-2763-8.

18.

B-cell receptor reconstruction from single-cell RNA-seq with VDJPuzzle.

Rizzetto S, Koppstein DNP, Samir J, Singh M, Reed JH, Cai CH, Lloyd AR, Eltahla AA, Goodnow CC, Luciani F.

Bioinformatics. 2018 Aug 15;34(16):2846-2847. doi: 10.1093/bioinformatics/bty203.

PMID:
29659703
19.

Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study.

Kelly ML, Riordan SM, Bopage R, Lloyd AR, Post JJ.

PLoS One. 2018 Feb 13;13(2):e0192763. doi: 10.1371/journal.pone.0192763. eCollection 2018.

20.

Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review.

Bartlett SR, Grebely J, Eltahla AA, Reeves JD, Howe AYM, Miller V, Ceccherini-Silberstein F, Bull RA, Douglas MW, Dore GJ, Harrington P, Lloyd AR, Jacka B, Matthews GV, Wang GP, Pawlotsky JM, Feld JJ, Schinkel J, Garcia F, Lennerstrand J, Applegate TL.

Hepatol Commun. 2017 May 22;1(5):379-390. doi: 10.1002/hep4.1050. eCollection 2017 Jul. Review.

21.

Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study.

Cunningham EB, Hajarizadeh B, Amin J, Bretana N, Dore GJ, Degenhardt L, Larney S, Luciani F, Lloyd AR, Grebely J; HITS-p Investigators.

Int J Drug Policy. 2018 Apr;54:18-25. doi: 10.1016/j.drugpo.2017.12.013. Epub 2018 Jan 24.

PMID:
29367011
22.

Autonomic nervous system function, activity patterns, and sleep after physical or cognitive challenge in people with chronic fatigue syndrome.

Cvejic E, Sandler CX, Keech A, Barry BK, Lloyd AR, Vollmer-Conna U.

J Psychosom Res. 2017 Dec;103:91-94. doi: 10.1016/j.jpsychores.2017.10.010. Epub 2017 Oct 19.

PMID:
29167053
23.

Cytokine signature in chronic fatigue syndrome.

Roerink ME, Buckland M, Lloyd AR, van der Meer JWM.

Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):E9435. doi: 10.1073/pnas.1714011114. Epub 2017 Oct 30. No abstract available.

24.

The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative.

Esmaeili A, Mirzazadeh A, Morris MD, Hajarizadeh B, Sacks HS, Maher L, Grebely J, Kim AY, Lauer G, Cox AL, Hellard M, Dietze P, Bruneau J, Shoukry NH, Dore GJ, Lloyd AR, Prins M, Page K; InC3 Collaborative.

Clin Infect Dis. 2018 Jan 6;66(1):20-28. doi: 10.1093/cid/cix768.

25.

Impact of sequencing depth and read length on single cell RNA sequencing data of T cells.

Rizzetto S, Eltahla AA, Lin P, Bull R, Lloyd AR, Ho JWK, Venturi V, Luciani F.

Sci Rep. 2017 Oct 6;7(1):12781. doi: 10.1038/s41598-017-12989-x.

26.

HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype.

Shepherd SJ, McDonald SA, Palmateer NE, Gunson RN, Aitken C, Dore GJ, Goldberg DJ, Applegate TL, Lloyd AR, Hajarizadeh B, Grebely J, Hutchinson SJ.

J Med Virol. 2018 Jan;90(1):120-130. doi: 10.1002/jmv.24919. Epub 2017 Sep 18.

PMID:
28843002
27.

Cognitive remediation training improves performance in patients with chronic fatigue syndrome.

McBride RL, Horsfield S, Sandler CX, Cassar J, Casson S, Cvejic E, Vollmer-Conna U, Lloyd AR.

Psychiatry Res. 2017 Nov;257:400-405. doi: 10.1016/j.psychres.2017.08.035. Epub 2017 Aug 18.

PMID:
28830024
28.

Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.

Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M, Roberts T, Crooks L, Midgard H, Larney S, Degenhardt L, Alho H, Byrne J, Dillon JF, Feld JJ, Foster G, Goldberg D, Lloyd AR, Reimer J, Robaeys G, Torrens M, Wright N, Maremmani I, Norton BL, Litwin AH, Dore GJ; International Network on Hepatitis in Substance Users.

Int J Drug Policy. 2017 Sep;47:51-60. doi: 10.1016/j.drugpo.2017.05.019. Epub 2017 Jul 3.

29.

Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer Fatigue.

Sandler CX, Goldstein D, Horsfield S, Bennett BK, Friedlander M, Bastick PA, Lewis CR, Segelov E, Boyle FM, Chin MTM, Webber K, Barry BK, Lloyd AR.

J Pain Symptom Manage. 2017 Jul;54(1):74-84. doi: 10.1016/j.jpainsymman.2017.03.015. Epub 2017 May 11.

PMID:
28502786
30.

Randomised controlled trial of online continuing education for health professionals to improve the management of chronic fatigue syndrome: a study protocol.

Li SH, Sandler CX, Casson SM, Cassar J, Bogg T, Lloyd AR, Barry BK.

BMJ Open. 2017 May 10;7(5):e014133. doi: 10.1136/bmjopen-2016-014133.

31.

Hepatitis C treatment as prevention: evidence, feasibility, and challenges.

Hajarizadeh B, Grebely J, Martinello M, Matthews GV, Lloyd AR, Dore GJ.

Lancet Gastroenterol Hepatol. 2016 Dec;1(4):317-327. doi: 10.1016/S2468-1253(16)30075-9. Epub 2016 Nov 10. Review.

PMID:
28404202
32.

Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study.

Cunningham EB, Hajarizadeh B, Bretana NA, Amin J, Betz-Stablein B, Dore GJ, Luciani F, Teutsch S, Dolan K, Lloyd AR, Grebely J; HITS-p investigators.

J Viral Hepat. 2017 Sep;24(9):733-741. doi: 10.1111/jvh.12701. Epub 2017 Apr 10.

PMID:
28256027
33.

Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment.

Eltahla AA, Leung P, Pirozyan MR, Rodrigo C, Grebely J, Applegate T, Maher L, Luciani F, Lloyd AR, Bull RA.

Sci Rep. 2017 Jan 31;7:41719. doi: 10.1038/srep41719.

34.

Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.

Rodrigo C, Walker MR, Leung P, Eltahla AA, Grebely J, Dore GJ, Applegate T, Page K, Dwivedi S, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Luciani F, Lloyd AR, Bull RA; InC(3) Study Group.

Infect Genet Evol. 2017 Apr;49:88-96. doi: 10.1016/j.meegid.2017.01.006. Epub 2017 Jan 5.

35.

Understanding the complex evolution of rapidly mutating viruses with deep sequencing: Beyond the analysis of viral diversity.

Leung P, Eltahla AA, Lloyd AR, Bull RA, Luciani F.

Virus Res. 2017 Jul 15;239:43-54. doi: 10.1016/j.virusres.2016.10.014. Epub 2016 Nov 22. Review.

PMID:
27888126
36.

A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies.

Bartlett SR, Wertheim JO, Bull RA, Matthews GV, Lamoury FM, Scheffler K, Hellard M, Maher L, Dore GJ, Lloyd AR, Applegate TL, Grebely J.

J Viral Hepat. 2017 May;24(5):404-411. doi: 10.1111/jvh.12652. Epub 2016 Nov 24.

37.

The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males.

Tsui JI, Mirzazadeh A, Hahn JA, Maher L, Bruneau J, Grebely J, Hellard M, Kim AY, Shoukry NH, Cox AL, Prins M, Dore GJ, Lauer G, Lloyd AR, Page K.

Drug Alcohol Depend. 2016 Dec 1;169:156-162. doi: 10.1016/j.drugalcdep.2016.10.024. Epub 2016 Oct 26.

38.

The natural history of acute Q fever: a prospective Australian cohort.

Hopper B, Cameron B, Li H, Graves S, Stenos J, Hickie I, Wakefield D, Vollmer-Conna U, Lloyd AR.

QJM. 2016 Oct;109(10):661-668. Epub 2016 Apr 1.

PMID:
27037328
39.

Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study.

Rodrigo C, Eltahla AA, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Shoukry NH, Lauer GM, Maher L, Schinkel J, Prins M, Hellard M, Lloyd AR; InC3 Collaborative.

J Viral Hepat. 2017 Jan;24(1):43-52. doi: 10.1111/jvh.12616. Epub 2016 Nov 3.

40.

Gene Expression in Response to Exercise in Patients with Chronic Fatigue Syndrome: A Pilot Study.

Keech A, Vollmer-Conna U, Barry BK, Lloyd AR.

Front Physiol. 2016 Sep 22;7:421. eCollection 2016.

41.

Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.

Eltahla AA, Rodrigo C, Betz-Stablein B, Grebely J, Applegate T, Luciani F, Schinkel J, Dore GJ, Page K, Bruneau J, Morris MD, Cox AL, Kim AY, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Lloyd AR, Bull RA; InC3 Study Group.

J Viral Hepat. 2017 Jan;24(1):37-42. doi: 10.1111/jvh.12615. Epub 2016 Sep 25.

42.

Outcomes and predictors of response from an optimised, multidisciplinary intervention for chronic fatigue states.

Sandler CX, Hamilton BA, Horsfield SL, Bennett BK, Vollmer-Conna U, Tzarimas C, Lloyd AR.

Intern Med J. 2016 Dec;46(12):1421-1429. doi: 10.1111/imj.13251.

PMID:
27620986
43.

The Prison Economy of Needles and Syringes: What Opportunities Exist for Blood Borne Virus Risk Reduction When Prices Are so High?

Treloar C, McCredie L, Lloyd AR.

PLoS One. 2016 Sep 9;11(9):e0162399. doi: 10.1371/journal.pone.0162399. eCollection 2016.

44.

Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia.

Rodrigo C, Eltahla AA, Bull RA, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Estes C, Razavi H, Lloyd AR, Luciani F; International Collaborative of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study Group.

J Infect Dis. 2016 Nov 1;214(9):1383-1389. Epub 2016 Aug 28.

45.

Hepatitis C-specific effector and regulatory CD4 T-cell responses are associated with the outcomes of primary infection.

Keoshkerian E, Hunter M, Cameron B, Nguyen N, Sugden P, Bull R, Zekry A, Maher L, Seddiki N, Zaunders J, Kelleher A, Lloyd AR; HITS-p and HITS-c investigators.

J Viral Hepat. 2016 Dec;23(12):985-993. doi: 10.1111/jvh.12576. Epub 2016 Aug 25.

PMID:
27558465
46.

HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection.

Lamoury FM, Hajarizadeh B, Keoshkerian E, Feld JJ, Amin J, Teutsch S, Matthews GV, Hellard M, Dore GJ, Lloyd AR, Applegate TL, Grebely J; ATAHC Study Group.

BMC Infect Dis. 2016 Jun 1;16:241. doi: 10.1186/s12879-016-1567-2.

47.

Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection.

Sheridan DA, Hajarizadeh B, Fenwick FI, Matthews GV, Applegate T, Douglas M, Neely D, Askew B, Dore GJ, Lloyd AR, George J, Bassendine MF, Grebely J.

Liver Int. 2016 Dec;36(12):1774-1782. doi: 10.1111/liv.13176. Epub 2016 Jul 5.

PMID:
27224844
48.

Fatigue Exacerbation by Interval or Continuous Exercise in Chronic Fatigue Syndrome.

Sandler CX, Lloyd AR, Barry BK.

Med Sci Sports Exerc. 2016 Oct;48(10):1875-85. doi: 10.1249/MSS.0000000000000983.

PMID:
27183124
49.

Incident Hepatitis C Virus Genotype Distribution and Multiple Infection in Australian Prisons.

Walker MR, Li H, Teutsch S, Betz-Stablein B, Luciani F, Lloyd AR, Bull RA.

J Clin Microbiol. 2016 Jul;54(7):1855-1861. doi: 10.1128/JCM.00287-16. Epub 2016 May 11.

50.

Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in europeans.

Asimakopoulos A, Mangia A, Dore GJ, Lloyd AR, George J, Eslam M.

Hepatology. 2016 Dec;64(6):2264-2265. doi: 10.1002/hep.28626. Epub 2016 Jun 27. No abstract available.

PMID:
27121959

Supplemental Content

Loading ...
Support Center